TREM1/Dap12-based CAR-T cells show potent antitumor activity
Researchers from Nanjing (China) have produced an alternative CAR construct for the treatment of solid tumors and have presented their results in Immunotherapy.
CAR-T cell therapies have been shown to have incredible promise when utilized to treat blood cancers, with recent clinical trials suggesting over a 90% response rate in resistant lymphomas; however, there has been limited progress in utilizing the therapy in the treatment of solid tumors.
To tackle the poor efficacy in solid tumors, a team of researchers designed an alternative chimeric antigen receptor (CAR). The research team, a collaboration of researchers from The Affiliated Hospital of Nanjing University Medical School, Nanjing Aide Institute of Immunotherapy and Nanjing CART Medical Technology (all China), came together to produce more efficient CAR-T cells.
The new CAR was designed by combining a single-chain variable fragment (scFv) with both triggering receptor expressed on myeloid 1 (TREM1) and DNAX activation protein 12 (DAP12). This new construct was then introduced into T-cells.
After creating the novel CAR-T cells, the researchers tested the product with in vitro assays and in vivo models.
The team’s results were published in Immunotherapy and are now available free of charge for RegMedNet members.
Have any additional questions about this story? Ask us in the comments, below.
Find out more in these top picks from the Editor:
- Scaling allogeneic therapies: an interview with Senthil Ramaswamy
- Challenges and opportunities for allogeneic CAR-T therapies
- How to choose the best medium for CAR-T manufacturing